IC14 Flashcards

(33 cards)

1
Q

Role of Vit D

A

helps Calcium to be absorbed from GIT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What happens when there is low Ca

A

PTH secretion will incr, causing incr bone resorption and reabsorption of Ca in renal distal tubule

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

At clinical doses, PTH analogues act more like a _____

A

anabolic agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Osteoclast stimulates bone____

A

resorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Osteoblast stimulates bone___

A

growth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

RANKL and sclerostin are produced by ____

A

osteocyte

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Role of sclerostin

A

Sclerostin binds to osteoblast -> inhibit WNT signalling -> repress dy/dx of osteoblast & ability to grow new bone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Role of RANKL

A

Stimulates osteoclast to break down bone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Example of RANKL inhibitor

A

Denosumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Role of anti-resorptive agents

A

Blocks bone breakdown

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Examples of anti-resorptive agents

A
  • Bisphosphonates
  • denosumab
  • oestrogen
  • calcitonin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

MOA of bisphosphonates

A

Slow bone loss by incr osteoclast cell death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

In what situation is bisphosphonate use > 5 years appropriate?

A

10yr total fracture risk > 20% OR prior vertebrae fracture

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

MOA of denosumab

A

Human mAb Inhibits RANKL -> prevents osteoclast development

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Administration of denosumab (route & frequency)

A

SC injection every 6 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What to co-administer with denosumab

A

1000mg Ca +/- (min) 400 IU vit D daily

17
Q

Discontinuation of denosumab may cause ___

A

Risk of spinal column fractures

18
Q

Oestrogens MOA

A

Helps maintain bone density

19
Q

What is raloxifene

A

Selective oestrogen receptor modulator

20
Q

MOA of raloxifene

A

Mixed oestrogen receptor agonism and antagonism
-> Mimics effects of oestrogen on bone density in postmenopausal women.

21
Q

Risk of using oestrogen therapy

A
  1. Incr risk of breast cancer
  2. Incr risk of blood clots
22
Q

What is calcitonin and how is it secreted

A

Peptide hormone secreted by parafollicular cells of thyroid gland

23
Q

Dosage forms for calcitonin

A

IV/ IM/ SC/ nasal spray route

24
Q

Examples of anabolic agents

A
  • romosozumab
  • parathyroid hormone therapy
25
MOA of romosozumab
Humainised mouse mAb -> inhibits sclerostin activity -> incr bone formation & decr bone resorption
26
Administration of romosozumab
SC injection once a month
27
When is romosozumab used
For women at high fracture risk / those who failed or intolerant to other therapies
28
Example of Parathyroid hormone similars
teriparatide
29
Administration of Parathyroid hormone similars
Once daily SC injection
30
Max tx duration for parathyroid hormone similars
24 months
31
IV zoledronate administration
Once a year
32
Oral alendronate administration
Once a week
33
Oral risedronate administration
Once a week or month